{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:53:17Z","timestamp":1777449197872,"version":"3.51.4"},"reference-count":144,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT \u2013 Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["UID\/QUI\/00062\/2013"],"award-info":[{"award-number":["UID\/QUI\/00062\/2013"]}]},{"name":"UID\/QUI\/00062\/2013","award":["UID\/BIA\/00329\/2013"],"award-info":[{"award-number":["UID\/BIA\/00329\/2013"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer is a multistage process resulting in an uncontrolled and abrupt division of cells and is one of the leading causes of mortality. The cases reported and the predictions for the near future are unthinkable. Food and Drug Administration data showed that 40% of the approved molecules are natural compounds or inspired by them, from which, 74% are used in anticancer therapy. In fact, natural products are viewed as more biologically friendly, that is less toxic to normal cells. In this review, the most recent and successful cases of secondary metabolites, including alkaloid, diterpene, triterpene and polyphenolic type compounds, with great anticancer potential are discussed. Focusing on the ones that are in clinical trial development or already used in anticancer therapy, therefore successful cases such as paclitaxel and homoharringtonine (in clinical use), curcumin and ingenol mebutate (in clinical trials) will be addressed. Each compound\u2019s natural source, the most important steps in their discovery, their therapeutic targets, as well as the main structural modifications that can improve anticancer properties will be discussed in order to show the role of plants as a source of effective and safe anticancer drugs.<\/jats:p>","DOI":"10.3390\/ijms19010263","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T04:23:44Z","timestamp":1516163024000},"page":"263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":560,"title":["Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-2375","authenticated-orcid":false,"given":"Ana","family":"Seca","sequence":"first","affiliation":[{"name":"cE3c\u2014Centre for Ecology, Evolution and Environmental Changes\/Azorean Biodiversity Group & Faculty of Sciences and Technology, University of Azores, Rua M\u00e3e de Deus, 9501-321 Ponta Delgada, Portugal"},{"name":"Department of Chemistry & QOPNA\u2014Organic Chemistry, Natural Products and Food Stuffs, University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal"}]},{"given":"Diana","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Chemistry & QOPNA\u2014Organic Chemistry, Natural Products and Food Stuffs, University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2018,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"World Health Organization (2017, October 02). Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs297\/en\/."},{"key":"ref_4","unstructured":"Stewart, B.W., and Wild, C.P. (2014). Transitions in human development and the global cancer burden. World Cancer Report 2014, International Agency for Research on Cancer."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Adeloye, D., David, R.A., Aderemi, A.V., Iseolorunkanmi, A., Oyedokun, A., Iweala, E.E., Omoregbe, N., and Ayo, C.K. (2016). An estimate of the incidence of prostate cancer in Africa: A systematic review and meta-analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153496"},{"key":"ref_6","first-page":"1","article-title":"North African medicinal plants traditionally used in cancer therapy","volume":"8","author":"Romane","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ptr.5751","article-title":"A systematic review on ethnomedicines of anticancer plants","volume":"31","author":"Tariq","year":"2017","journal-title":"Phytother. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/heapol\/czw022","article-title":"Use of traditional medicine in middle-income countries: A WHO-SAGE study","volume":"31","author":"Oyebode","year":"2016","journal-title":"Health Policy Plan."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.26501","article-title":"Traditional and complementary medicine used with curative intent in childhood cancer: A systematic review","volume":"64","author":"Diorio","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11684-017-0512-0","article-title":"Effect of traditional Chinese medicine combined with Western therapy on primary hepatic carcinoma: A systematic review with meta-analysis","volume":"11","author":"Ma","year":"2017","journal-title":"Front. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/1386207320666170116141818","article-title":"Anticancer properties of traditional Chinese medicine","volume":"20","author":"Yan","year":"2017","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_12","first-page":"327","article-title":"Herbal Medicines: Challenges in the modern world. Part 5. Status and current directions of complementary and alternative herbal medicine worldwide","volume":"10","author":"Enioutina","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1016\/j.ejmech.2011.07.057","article-title":"Natural products: An evolving role in future drug discovery","volume":"46","author":"Mishra","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s10495-015-1169-2","article-title":"Cell death mechanisms of plant-derived anticancer drugs: Beyond apoptosis","volume":"20","author":"Hmadi","year":"2015","journal-title":"Apoptosis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14513","DOI":"10.1007\/s13277-016-5364-8","article-title":"Natural products against cancer angiogenesis","volume":"37","author":"Khalid","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10295-015-1723-5","article-title":"Natural product discovery: Past, present and future","volume":"43","author":"Katz","year":"2016","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1248\/cpb.c15-00744","article-title":"Search for anti-angiogenic substances from natural sources","volume":"64","author":"Kotoku","year":"2016","journal-title":"Chem. Pharm. Bull."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bernardini, S., Tiezzi, A., Laghezza Masci, V., and Ovidi, E. (2017). Natural products for human health: An historical overview of the drug discovery approaches. Nat. Prod. Res.","DOI":"10.1080\/14786419.2017.1356838"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural products as sources of new drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J. Nat. Prod."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2013.00177","article-title":"The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety","volume":"4","author":"Ekor","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bjp.2014.03.006","article-title":"Traditional use and safety of herbal medicines","volume":"24","author":"Moreira","year":"2014","journal-title":"Rev. Bras. Farmacogn."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/1871520615666150520143827","article-title":"Exploring cancer therapeutics with natural products from African medicinal plants, Part II: Alkaloids, terpenoids and flavonoids","volume":"16","author":"Nwodo","year":"2016","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Habli, Z., Toumieh, G., Fatfat, M., Rahal, O.N., and Gali-Muhtasib, H. (2017). Emerging cytotoxic alkaloids in the battle against cancer: Overview of molecular mechanisms. Molecules, 22.","DOI":"10.3390\/molecules22020250"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Badal, S., and Delgoda, R. (2017). Evolutionary perspectives on the role of plant secondary metabolites. Pharmacognosy: Fundamentals, Applications and Strategies, Academic Press. [1st ed.].","DOI":"10.1016\/B978-0-12-802104-0.00007-X"},{"key":"ref_25","first-page":"377","article-title":"Plant secondary metabolites: Biosynthesis, classification, function and pharmacological properties","volume":"2","author":"Kabera","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.apsb.2016.06.003","article-title":"The modification of natural products for medical use","volume":"7","author":"Guo","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/17460441.2016.1272757","article-title":"The structural modification of natural products for novel drug discovery","volume":"12","author":"Yao","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/1097-0142(196310)16:10<1302::AID-CNCR2820161011>3.0.CO;2-A","article-title":"Vincristine in the treatment of acute leukaemia in children","volume":"16","author":"Evans","year":"1963","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/pbc.22161","article-title":"Vincristine: Can its therapeutic index be enhanced?","volume":"53","author":"Moore","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.3390\/molecules20022973","article-title":"Indole alkaloids from Catharanthus roseus: Bioproduction and their effect on human health","volume":"20","author":"Almagro","year":"2015","journal-title":"Molecules"},{"key":"ref_31","unstructured":"Naeem, M., Aftab, T., and Khan, M. (2017). Strategies for enhancing alkaloids yield in Catharanthus roseus via metabolic engineering approaches. Catharanthus Roseus: Current Research and Future Prospects, Springer International Publishing."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8742","DOI":"10.3390\/molecules17088742","article-title":"Negative-pressure cavitation extraction of four main vinca alkaloids from Catharanthus roseus leaves","volume":"17","author":"Mu","year":"2012","journal-title":"Molecules"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3109\/10717544.2015.1027015","article-title":"Are PEGylated liposomes better than conventional liposomes? A special case for vincristine","volume":"23","author":"Wang","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bcp.2010.12.026","article-title":"Molecular docking and pharmacogenomics of Vinca alkaloid and their monomeric precursor, vindoline and catharanthine","volume":"81","author":"Sertel","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.2015-0391","article-title":"Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukaemia","volume":"21","author":"Douer","year":"2016","journal-title":"Oncologist"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.04.004","article-title":"Vincristine-induced peripheral neuropathy in children with cancer: A systematic review","volume":"114","author":"Velde","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ped.13229","article-title":"Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin","volume":"59","author":"Yoshihara","year":"2017","journal-title":"Pediatr. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijpharm.2017.05.016","article-title":"Paclitaxel: What has been done and the challenges remain ahead","volume":"526","author":"Bernabeu","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.colsurfb.2016.01.003","article-title":"Novel Soluplus1\u00ae-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines","volume":"140","author":"Bernabeu","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.nbt.2014.02.010","article-title":"Paclitaxel: Biosynthesis, production and future prospects","volume":"31","author":"Howat","year":"2014","journal-title":"New Biotechnol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/367630a0","article-title":"Total synthesis of taxol","volume":"367","author":"Nicolaou","year":"1994","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1021\/acs.orglett.5b01174","article-title":"Synthesis of Paclitaxel. 2. Construction of the ABCD ring and formal synthesis","volume":"17","author":"Fukaya","year":"2015","journal-title":"Org. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/chem.201404295","article-title":"Formal total synthesis of (\u2212)-taxol through Pd-catalyzed eight-membered carbocyclic ring formation","volume":"21","author":"Hirai","year":"2015","journal-title":"Chemistry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11240-016-1164-5","article-title":"Taxol from Corylus avellana: Paving the way for a new source of this anti-cancer drug","volume":"129","author":"Gallego","year":"2017","journal-title":"Plant Cell Tissue Organ Cult."},{"key":"ref_46","first-page":"1","article-title":"Improving 10-deacetylbaccatin III-10-\u03b2-O-acetyltransferase catalytic fitness for Taxol production","volume":"8","author":"Li","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/np990040k","article-title":"A new semisynthesis of paclitaxel from baccatin III","volume":"62","author":"Baloglu","year":"1999","journal-title":"J. Nat. Prod."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0040-4039(99)02056-0","article-title":"A semisynthesis of paclitaxel via a 10-deacetylbaccatin III derivative bearing a \u03b2-keto ester appendage","volume":"41","author":"Mandai","year":"2000","journal-title":"Tetrahedron Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"48800","DOI":"10.1039\/C6RA06640B","article-title":"Advances in exploring alternative Taxol sources","volume":"6","author":"Liu","year":"2016","journal-title":"RSC Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/med.21377","article-title":"Strategies for the optimization of natural leads to anticancer drugs or drug candidates","volume":"36","author":"Xiao","year":"2016","journal-title":"Med. Res. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.7314\/APJCP.2013.14.9.4983","article-title":"Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line","volume":"14","author":"Wang","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.3390\/cancers7040897","article-title":"Paclitaxel through the ages of anticancer therapy: Exploring its role in chemoresistance and radiation therapy","volume":"7","author":"Barbuti","year":"2015","journal-title":"Cancers"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2174\/1567201811666140609154949","article-title":"Paclitaxel formulations: Challenges and novel delivery options","volume":"11","author":"Nehate","year":"2014","journal-title":"Curr. Drug Deliv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/OTT.S122974","article-title":"nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors","volume":"10","author":"Soliman","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17360","DOI":"10.18632\/oncotarget.14477","article-title":"Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: A systematic review and meta-analysis","volume":"8","author":"Zong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.7314\/APJCP.2013.14.4.2591","article-title":"Clinical comparison between paclitaxel liposome (Lipusu\u00ae) and paclitaxel for treatment of patients with metastatic gastric cancer","volume":"14","author":"Xu","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00280-014-2607-5","article-title":"Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer","volume":"75","author":"Rivera","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.fitote.2016.02.010","article-title":"Recent advances in design, synthesis and bioactivity of paclitaxel-mimics","volume":"110","author":"Wen","year":"2016","journal-title":"Fitoterapia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1634\/theoncologist.9-suppl_2-24","article-title":"Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience","volume":"9","author":"Crown","year":"2004","journal-title":"Oncologist"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/DDDT.S64940","article-title":"Preclinical profile of cabazitaxel","volume":"8","author":"Vrignaud","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/pros.23182","article-title":"Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation","volume":"76","author":"Aghai","year":"2016","journal-title":"Prostate"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428194.2017.1330954","article-title":"Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: Results of a phase-I study","volume":"59","author":"Goyal","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-017-0662-3","article-title":"Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts","volume":"16","author":"Ricci","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jddst.2016.10.005","article-title":"EGFR targeted delivery of paclitaxel and parthenolide co-loaded in PEG-Phospholipid micelles enhance cytotoxicity and cellular uptake in non-small cell lung cancer cells","volume":"36","author":"Gill","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jaad.2003.09.018","article-title":"Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study","volume":"50","author":"Ehrlich","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1021\/jm301829h","article-title":"Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A","volume":"56","author":"Dadgar","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.clml.2013.03.017","article-title":"Homoharringtonine\/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval","volume":"13","author":"Kantarjian","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1039\/C4NP00064A","article-title":"Natural product and natural product derived drugs in clinical trials","volume":"31","author":"Butler","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/B978-0-444-63930-1.00010-7","article-title":"Chemistry, bioactivity, and the structure-activity relationship of cephalotaxine-type alkaloids from Cephalotaxus sp.","volume":"Volume 53","year":"2017","journal-title":"Studies in Natural Products Chemistry Bioactive Natural Products"},{"key":"ref_70","first-page":"1","article-title":"Homoharringtonine and omacetaxine for myeloid hematological malignancies","volume":"7","author":"Wang","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1078-0432.CCR-13-1283","article-title":"Omacetaxine: A protein translation inhibitor for treatment of chronic myelogenous leucemia","volume":"20","author":"Gandhi","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"12764","DOI":"10.18632\/oncotarget.14463","article-title":"The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukaemia","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"40318","DOI":"10.18632\/oncotarget.16956","article-title":"Homoharringtonine targets Smad3 and TGF-\u03b2 pathway to inhibit the proliferation of acute myeloid leukaemia cells","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2017.01.005","article-title":"Current approach to the treatment of chronic myeloid leukaemia","volume":"55","author":"Pasic","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2146\/ajhp130506","article-title":"Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukaemia","volume":"71","author":"Chung","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/cncr.29240","article-title":"Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukaemia: Results with 24 months of follow-up","volume":"121","author":"Cortes","year":"2015","journal-title":"Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/14740338.2016.1207760","article-title":"A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukaemia","volume":"15","author":"Damlaj","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.55","article-title":"Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem\/progenitor cells","volume":"25","author":"Allan","year":"2011","journal-title":"Leukaemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaf3735","article-title":"Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukaemia","volume":"8","author":"Lam","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.leukres.2014.05.007","article-title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukaemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives","volume":"38","author":"Heiblig","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2014-0230","article-title":"Updated product label allows home administration of omacetaxine mepesuccinate","volume":"19","author":"Shen","year":"2014","journal-title":"Oncologist"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3109\/10428194.2015.1071486","article-title":"Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukaemia treated with omacetaxine mepesuccinate","volume":"57","author":"Akard","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drudis.2007.10.010","article-title":"Plant-derived compounds in clinical trials","volume":"13","author":"Saklani","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0031-9422(00)81076-6","article-title":"Biologically active diterpene esters from Euphorbia peplus","volume":"24","author":"Rizk","year":"1985","journal-title":"Phytochemistry"},{"key":"ref_85","first-page":"633","article-title":"The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers","volume":"164","author":"Ramsay","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.fitote.2014.07.002","article-title":"The value of nature\u2019s natural product library for the discovery of new chemical entities: The discovery of ingenol mebutate","volume":"98","author":"Ogbourne","year":"2014","journal-title":"Fitoterapia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/pca.2711","article-title":"Quantitative analysis of ingenol in Euphorbia species via validated isotope dilution ultra-high performance liquid chromatography tandem mass spectrometry","volume":"29","author":"Dragull","year":"2018","journal-title":"Phytochem. Anal."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1055\/s-0032-1317415","article-title":"Semisynthesis of ingenol 3-angelate (PEP005): Efficient stereoconservative angeloylation of alcohols","volume":"23","author":"Liang","year":"2012","journal-title":"Synlett"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1016\/j.bmcl.2013.08.038","article-title":"Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer","volume":"23","author":"Liang","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/1535-7163.MCT-07-2060","article-title":"Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells","volume":"7","author":"Serova","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1038\/sj.bjc.6604642","article-title":"Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells","volume":"99","author":"Benhadji","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2217\/cpr.14.13","article-title":"Ingenol mebutate: A novel treatment for actinic keratosis","volume":"11","author":"Collier","year":"2014","journal-title":"Clin. Pract."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2010.12.038","article-title":"Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response","volume":"66","author":"Rosen","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_94","first-page":"45","article-title":"Natural products as lead protein kinase c modulators for cancer therapy","volume":"Volume 53","year":"2017","journal-title":"Studies in Natural Products Chemistry Bioactive Natural Products"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1158\/0008-5472.CAN-03-3403","article-title":"Characterization of the interaction of ingenol 3-angelate with protein kinase C","volume":"64","author":"Kedei","year":"2004","journal-title":"Cancer Res."},{"key":"ref_96","first-page":"1156","article-title":"Ingenol mebutate: Potential for further development of cancer immunotherapy","volume":"11","author":"Doan","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1684\/ejd.2014.2368","article-title":"The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP)","volume":"24","author":"Tzogani","year":"2014","journal-title":"Eur. J. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1080\/10408398.2015.1077195","article-title":"Curcumin, an active component of turmeric (Curcuma longa), and its effects on health","volume":"57","author":"Kocaadam","year":"2017","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0731-7085(96)02024-9","article-title":"Stability of curcumin in buffer solutions and characterization of its degradation products","volume":"15","author":"Wang","year":"1997","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_100","first-page":"222","article-title":"Cancer risk and diet in India","volume":"49","author":"Sinha","year":"2003","journal-title":"J. Postgrad. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/etm.2015.2749","article-title":"Biological and therapeutic activities and anticancer properties of curcumin","volume":"10","author":"Perrone","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Pavan, A.R., Silva, G.D., Jornada, D.H., Chiba, D.E., Fernandes, G.F., Man Chin, C., and Dos Santos, J.L. (2016). Unraveling the anticancer effect of curcumin and resveratrol. Nutrients, 8.","DOI":"10.3390\/nu8110628"},{"key":"ref_103","first-page":"1","article-title":"Cucurmin, anticancer and antitumor perspectives\u2014A comprehensive review","volume":"22","author":"Imran","year":"2016","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_104","first-page":"1","article-title":"New insights toward colorectal cancer chemotherapy using natural bioactive compounds","volume":"8","author":"Villar","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jop.12455","article-title":"In vivo and in vitro effects of curcumin on head and neck carcinoma: A systematic review","volume":"46","author":"Borges","year":"2017","journal-title":"J. Oral Pathol. Med."},{"key":"ref_106","first-page":"599","article-title":"Curcumin and cancer stem cells: Curcumin has asymmetrical effects on cancer and normal stem cells","volume":"35","author":"Sordillo","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_107","first-page":"1","article-title":"Protective effect of curcumin on neural myelin sheaths by attenuating interactions between the endoplasmic reticulum and mitochondria after compressed spinal cord","volume":"5","author":"Yu","year":"2016","journal-title":"J. Spine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/13543776.2017.1276566","article-title":"Recent progress on curcumin-based therapeutics: A patent review (2012\u20132016). Part I: Curcumin","volume":"27","author":"Luppi","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.lfs.2016.02.022","article-title":"Molecular mechanisms underlying chemopreventive potential of curcumin: Current challenges and future perspectives","volume":"148","author":"Kumar","year":"2016","journal-title":"Life Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1042\/CS20160935","article-title":"Curcumin mediates anticancer effects by modulating multiple cell signaling pathways","volume":"131","author":"Kunnumakkara","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00432-017-2380-z","article-title":"Curcumin induces G2\/M arrest, apoptosis, NF-\u03baB inhibition, and expression of differentiation genes in thyroid carcinoma cells","volume":"143","author":"Schwertheim","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/DDDT.S126964","article-title":"Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation","volume":"11","author":"Yang","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.biopha.2016.12.034","article-title":"Curcumin inhibits growth potential by G1 cell cycle arrest and induces apoptosis in p53-mutated COLO 320DM human colon adenocarcinoma cells","volume":"86","author":"Dasiram","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00595-015-1129-z","article-title":"Effect of NF-\u03baB inhibition on chemoresistance in biliary\u2013pancreatic cancer","volume":"45","author":"Uwagawa","year":"2015","journal-title":"Surg. Today"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"19469","DOI":"10.18632\/oncotarget.3625","article-title":"Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway","volume":"6","author":"Fu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.saa.2016.11.049","article-title":"A comprehensive approach to ascertain the binding mode of curcumin with DNA","volume":"175","author":"Haris","year":"2017","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejmech.2016.12.043","article-title":"Synthesis and biological evaluation of curcumin inspired indole analogues as tubulin polymerization inhibitors","volume":"127","author":"Ramya","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1208\/s12248-012-9432-8","article-title":"Therapeutic roles of curcumin: Lessons learned from clinical trials","volume":"15","author":"Gupta","year":"2013","journal-title":"AAPS J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijpharm.2016.08.003","article-title":"Doxorubicin enhances curcumin\u2019s cytotoxicity in human prostate cancer cells in vitro by enhancing its cellular uptake","volume":"514","author":"Klippstein","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.3892\/ol.2016.5217","article-title":"Curcumin potentiates the effect of chemotherapy against acute lymphoblastic leukaemia cells via downregulation of NF-\u03baB","volume":"12","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_121","first-page":"383","article-title":"Novel delivery system for natural products: Nano-curcumin formulations","volume":"6","author":"Rahimi","year":"2016","journal-title":"Avicenna J. Phytomed."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/1061186X.2016.1157883","article-title":"Oral bioavailability of curcumin: Problems and advancements","volume":"24","author":"Liu","year":"2016","journal-title":"J. Drug Target"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1007\/s00044-016-1628-5","article-title":"Synthesis and antiproliferative studies of curcumin pyrazole derivatives","volume":"25","author":"Puneeth","year":"2016","journal-title":"Med. Chem. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/cbdd.12682","article-title":"Betulinic acid: Recent advances in chemical modifications, effective delivery, and molecular mechanisms of a promising anticancer therapy","volume":"87","author":"Jantan","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1081\/SCC-200034788","article-title":"Selective oxidation of betulin for the preparation of betulinic acid, an antitumoral compound","volume":"34","author":"Pichette","year":"2004","journal-title":"Synth. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"99","DOI":"10.15835\/nbha4027967","article-title":"Evaluation of betulin and betulinic acid content in birch bark from different forestry areas of western carpathians","volume":"40","author":"Holonec","year":"2012","journal-title":"Not. Bot. Horti Agrobot."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nm1095-1046","article-title":"Discovery of betulinic acid a selective inhibitor of human-melanoma that functions by induction of apoptosis","volume":"10","author":"Pisha","year":"1995","journal-title":"Nat. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpls.2016.01667","article-title":"Lead phytochemicals for anticancer drug development","volume":"7","author":"Singh","year":"2016","journal-title":"Front. Plant Sci."},{"key":"ref_129","first-page":"199","article-title":"Recent studies on betulinic acid and its biological and pharmacological activity","volume":"14","author":"Lee","year":"2015","journal-title":"EXCLI J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21353","article-title":"Betulinic acid and its derivatives as potential antitumor agents","volume":"35","author":"Zhang","year":"2015","journal-title":"Med. Res. Rev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"936","DOI":"10.2174\/1871520614666140223192148","article-title":"Betulinic acid as a potent and complex antitumor phytochemical: A minireview","volume":"14","author":"Gheorgheosu","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"242","DOI":"10.13005\/ojc\/330128","article-title":"Synthesis, characterization and cytotoxic activity of betulinic acid and sec-betulinic acid derivatives against human colorectal carcinoma","volume":"33","author":"Ali","year":"2017","journal-title":"Orient. J. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.biopha.2016.10.018","article-title":"Multiple molecular targets in breast cancer therapy by betulinic acid","volume":"84","author":"Luo","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Shankar, E., Zhang, A., Franco, D., and Gupta, S. (2017). Betulinic acid-mediated apoptosis in human prostate cancer cells involves p53 and nuclear factor-kappa b (NF-\u03baB) pathways. Molecules, 22.","DOI":"10.3390\/molecules22020264"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/onc.2015.102","article-title":"Betulinic acid induces a novel cell death pathway that depends on cardiolipin modification","volume":"35","author":"Potze","year":"2016","journal-title":"Oncogene"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Waechter, F., Silva, G.S., Willig, J., de Oliveira, C.B., Vieira, B.D., Trivella, D.B., Zimmer, A.R., Buffon, A., Pilger, D.A., and Gnoatto, S. (2017). Design, synthesis, and biological evaluation of betulinic acid derivatives as new antitumor agents for leukaemia. Anticancer Agents Med. Chem.","DOI":"10.2174\/1871521409666170412143638"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1742-7843.2007.00115.x","article-title":"Effect of betulinic acid on anticancer drug-resistant colon cancer cells","volume":"101","author":"Jung","year":"2007","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/0008-5472.CAN-10-2016","article-title":"Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis","volume":"71","author":"Gao","year":"2011","journal-title":"Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopha.2017.01.034","article-title":"Betulinic acid promotes TRAIL function on liver cancer progression inhibition through p53\/Caspase-3 signaling activation","volume":"88","author":"Xu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2174\/0929867053202214","article-title":"Betulinic acid and its derivatives: A review on their biological properties","volume":"12","author":"Yogeeswari","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.biomaterials.2014.10.057","article-title":"Nanodiamonds coupled with plant bioactive metabolites: A nanotech approach for cancer therapy","volume":"38","author":"Gismondi","year":"2015","journal-title":"Biomaterials"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/IJN.S96614","article-title":"Nanodiamonds coupled with 5,7-dimethoxycoumarin, a plant bioactive metabolite, interfere with the mitotic process in B16F10 cells altering the actin organization","volume":"11","author":"Gismondi","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2741\/s473","article-title":"Cancer treatment with nano-diamonds","volume":"9","author":"Gupta","year":"2017","journal-title":"Front. Biosci. (Sch. Ed.)"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1389450116666150722141607","article-title":"Nanocarriers based anticancer drugs: Current scenario and future perceptions","volume":"17","author":"Raj","year":"2016","journal-title":"Curr. Drug Targets"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/1\/263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:51:30Z","timestamp":1760194290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/1\/263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,16]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"alternative-id":["ijms19010263"],"URL":"https:\/\/doi.org\/10.3390\/ijms19010263","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,16]]}}}